The Utility of Domain-Specific End Points in Acute Stroke Trials

Steven C. Cramer; Steven L. Wolf; Jeffrey L. Saver; Karen C. Johnston; J. Mocco; Maarten G. Lansberg; Sean I. Savitz; David S. Liebeskind; Wade Smith; Max Wintermark; Jordan J. Elm; Pooja Khatri; Joseph P. Broderick; Scott Janis; S. J. Mocco; David S. Liebeskind; Wade Smith; Max Wintermark; Jordan J. Elm; Scott Janis; Edward C. Jauch; Enrique C. Leira; Renee Martin; Brett C. Meyer; Kiva Schindler; Phillip Scott; Aneesh B. Singhal; Claudia S. Moy

Article

The Utility of Domain-Specific End Points in Acute Stroke Trials

Stroke

DOI: 10.1161/STROKEAHA.120.031939

23Citations

19Readers

Get full text

Author supplied keywords

Cite

CITATION STYLE

APA

Cramer, S. C., Wolf, S. L., Saver, J. L., Johnston, K. C., Mocco, J., Lansberg, M. G., … Moy, C. S. (2021). The Utility of Domain-Specific End Points in Acute Stroke Trials. Stroke. Wolters Kluwer Health. https://doi.org/10.1161/STROKEAHA.120.031939

The Utility of Domain-Specific End Points in Acute Stroke Trials

Author supplied keywords

Cite

Register to see more suggestions